Close

pCDCAR1 ROR1 h(BBζ, α/β/γ) (CAR-LC338)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-ROR1 chimeric antigen receptor (CAR) is based on the FcεRI receptor scaffold and constructed for the engineering of T cells to target human ROR1. The T cells are genetically modified through transduction with a lentiviral vector expressing an alpha chain composed of scFv of anti-ROR1 antibody and FcεR1α-SP, a beta chain composed of 4-1BB signaling domain and FcεR1β-ΔITAM, and a gamma chain composed of CD3ζ signaling domain and FcεR1γ-SP-ΔITAM. And the vector product was designed for the treatment of multiple myeloma.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • ROR1
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • B cell-chronic lymphocytic leukemia
  • Generation
  • Second
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral
  • Receptor Construction
  • FcεR1α-SP-scFv/FcεR1β-ΔITAM-41BB/FcεR1γ-SP-ΔITAM-CD3ζ
  • Discription of Signaling Cassetes
  • 41BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • 2A2
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • Receptor tyrosine kinase like orphan receptor 1
  • Synonyms
  • ROR1; NTRKR1; dJ537F10.1

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
CAR scFv data ELISA

Fig.1 Specificity and epitope mapping of anti-hROR1 mAbs.

CAR Construction : Latest CAR Construction

Fig.1 Specificity and epitope mapping of anti-hROR1 mAbs.

ELISA plates were coated with 100 ng/50 μL/well indicated recombinant fusion proteins.

Baskar, S., Wiestner, A., Wilson, W. H., Pastan, I., & Rader, C. (2012, May). Targeting malignant B cells with an immunotoxin against ROR1. In MAbs (Vol. 4, No. 3, pp. 349-361). Taylor & Francis.

CAR scFv data FCM

Fig.2 Flow cytometry analysis of surface ROR1 expression comparison between parental (left) and BCL2 overex.

CAR Construction : Latest CAR Construction

Fig.2 Flow cytometry analysis of surface ROR1 expression comparison between parental (left) and BCL2 overex.

. HuXBR1-402-G5-PNU synergizes with the BCL2 inhibitor venetoclax.

Hu, E. Y., Do, P., Goswami, S., Nunes, J., Chiang, C. L., Elgamal, S., ... & Muthusamy, N. (2021). The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia. Blood advances, 5(16), 3152-3162.

CAR scFv data FuncS

Fig.3 Competition assay using anti-ROR1 monoclonal antibody (clone 2A2).

CAR Construction : Latest CAR Construction

Fig.3 Competition assay using anti-ROR1 monoclonal antibody (clone 2A2).

Histograms show the binding of anti-ROR1 2A2 monoclonal antibodies to cell surface ROR1 protein.

Daikuzono, H., Yamazaki, M., Sato, Y., Takahashi, T., & Yamagata, K. (2021). Development of a DELFIA method to detect oncofetal antigen ROR1-positive exosomes. Biochemical and Biophysical Research Communications, 578, 170-176.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-ROR1 (2A2) h(41BB/CD3ζ) Multi-chain CAR, pCDCAR1 (CAR-LC338). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.